Research ArticleArticle

Physiological and Pathophysiological Regulation of Cytochrome P450

Edward T. Morgan, Marion B. Sewer, Heinrich Iber, Frank J. Gonzalez, Ying-Hue Lee, Robert H. Tukey, Steve Okino, Tien Vu, Yue-Hwa Chen, Jaspreet S. Sidhu and Curtis J. Omiecinski
Drug Metabolism and Disposition December 1998, 26 (12) 1232-1240;

Abstract

This article is a report on a symposium sponsored by the American Society for Pharmacology and Experimental Therapeutics and held at the April 1998 Experimental Biology ’98 meeting in San Francisco. The presentations focused on the mechanisms of regulation of cytochrome P450 gene expression by developmental factors and by hormones and cytokines, as well as on the interplay between physiological and chemical regulation. Approaches and systems used to address these questions included conditional gene knockouts in mice, primary hepatocyte cultures, immunofluorescence imaging of cells, and cell lines stably expressing reporter gene constructs.

The expression of cytochrome P4501 genes in many species is highly regulated during development, by nutritional status, and by hormonal factors, including sex steroids, glucocorticoids, growth hormone, insulin, and inflammatory cytokines. Although the mechanisms and consequences of regulation of P450s by drugs and chemicals have been intensively studied, relatively little is known about the mechanisms by which P450s are regulated by physiological factors. This regulation has documented or potential consequences for pharmacokinetics of drugs in people and animals in different developmental stages, nutritional states, stress and disease states, different stages of the menstrual cycle, and between males and females.

This article summarizes four presentations (F.J.G., R.H.T., C.J.O., E.T.M.) at a symposium sponsored by the American Society for Pharmacology and Experimental Therapeutics at the April 1998 Experimental Biology ’98 meeting in San Francisco, chaired by one of the authors (E.T.M.). These articles highlight novel approaches and recent findings in the area of physiological regulation of P450 and in the interaction of physiological signaling pathways with those utilized by chemical agents.

Mechanisms of P450 Regulation by Inflammation, Cytokines, and Growth Factors (E.T.M., M.B.S., H.I.)

A large number of infectious or inflammatory agents have been shown to depress P450-catalyzed drug metabolism in humans and in experimental animals (Morgan, 1997). Many of these effects are accompanied by suppression of various P450 mRNAs, and this regulation can be mimicked by the action of inflammatory cytokines or interferons (from circulating monocyte/macrophages or from Kupffer cells) on the hepatocyte (Morgan, 1997). In a complex in vivo inflammatory response, many other factors may potentially affect P450 expression: for instance, actions of cytokines in the central nervous system affect the hypothalamo-pituitary axis (Bernton et al., 1987), resulting in altered secretion of glucocorticoids, thyroid hormones, and growth hormone, each of which regulates P450 expression (Morgan, 1997). Bacterial endotoxin (LPS) can also act directly on hepatocytes to downregulate P450 expression (Sewer and Morgan, 1997).

Despite the fact that many P450s are suppressed during inflammation or infection, it can be discerned from the literature that some are unaffected and some are induced (Sewer et al., 1997). Thus how an individual P450 is affected depends on the particular stimulus and the tissue being studied (Morgan, 1997). From this, we infer that specific mechanisms must exist for differential regulation of P450s in inflammation and infection. For the purposes of this presentation, we will focus on recent studies in our laboratory on the involvement of two well-characterized intracellular messengers in regulation of P450 expression.

CYP2C11 is the major P450 enzyme expressed in the livers of untreated male rats, and for this reason its regulation has been studied extensively in our laboratory and others. CYP2C11 is downregulated at the mRNA level by a variety of physiological and pathophysiological stimuli, including continuous growth hormone exposure (Morgan et al., 1985), inflammation (Sewer et al., 1997), stress (Merrill et al., 1992), fasting (Ma et al., 1989), and diabetes (Favreau and Schenkman, 1988). The effect of diabetes on CYP2C11 is partially due to the decrease in growth-hormone secretion in diabetic rats but also has a growth-hormone–independent component (Donahue et al., 1991). Inflammation, stress, fasting, and diabetes have in common an increase in the circulating glucagon/insulin ratio. Moreover, insulin is required for optimal expression of CYP2C11 in primary hepatocyte cultures, while the effects of glucagon have not been reported. Since glucagon and insulin, in part, exert many of their effects on cells through the modulation of cyclic AMP, we decided to investigate whether 2C11 expression could be regulated by this second messenger.

Incubation of rat hepatocytes cultured on matrigel with the cAMP derivatives dibutyryl cAMP, (Sp)-5,6-dichloro-1-β-D-ribofuranosylbenzimidazole-3′,5′-monophosphorothioate (Sp-cAMPS), and 8-(4-chlorophenylthio)-cAMP each caused a concentration-dependent downregulation of CYP2C11 mRNA. This effect was also seen with glucagon (which stimulates adenylate cyclase through its Gs-coupled membrane receptor) and forskolin (which stimulates adenylate cyclase directly). Together, these results indicate that agents which activate cAMP-dependent protein kinase (PKA) activity in cells can downregulate CYP2C11 expression. Rp-cAMPS is an inhibitor of cAMP activation of PKA by competing for binding to the regulatory subunit of PKA. Rp-cAMPS caused a parallel shift to the right of the concentration-response curve for CYP2C11 suppression by its diastereomer Sp-cAMPS, indicating the specificity of both agents. Furthermore, Rp-cAMPS completely blocked downregulation of CYP2C11 by glucagon and partially inhibited downregulation of CYP2C11 by interleukin (IL)-1. We also found that both the suppression of 2C11 expression and the elevation of cellular cAMP levels by glucagon were sensitive to the glucagon/insulin ratio, such that insulin attenuated the effects of glucagon on both parameters.

The fact that glucagon downregulates CYP2C11 expression via the adenylate cyclase/cAMP/PKA pathway and that this effect is modulated by insulin suggest that the increased glucagon/insulin ratio may contribute to the downregulation of this P450 during inflammation, stress, fasting, and diabetes. The observation that downregulation of CYP2C11 by IL-1 can be partially inhibited by Rp-cAMPS indicates that this cytokine utilizes more than one pathway to downregulate CYP2C11. In addition to cAMP, we have suggested that a sphingolipid messenger may also be involved in regulation of this P450 (Nikolova-Karakashian et al., 1997).

Nitric oxide is synthesized in large amounts in monocytes, macrophages, Kupffer cells, and hepatocytes during endotoxemia, because of the induction of inducible nitric oxide synthase (NOS2) by cytokines and LPS. NO has been implicated as a mediator of decreased cytochrome P450 catalytic activities and also in the suppression of P450 gene expression that occurs during endotoxemia, because inhibitors of NOS enzymes can block or attenuate the decreases seen in the mRNA or protein levels, or catalytic activities, of some P450 enzymes after an inflammatory stimulus (Carlson and Billings, 1996; Khatsenko and Kikkawa, 1997). We have tested the hypothesis that NO is required for inflammatory downregulation of P450 mRNAs and proteins, using in vivo and in vitro models to study the effects of NOS inhibitors on P450 suppression caused by LPS or cytokines. We have also studied the suppression of P450s in mice lacking a functional NOS2 gene. These experiments are described below. In contrast to those of other groups, our studies have failed to find a significant role for NO in these phenomena.

In rat hepatocytes cultured on Matrigel, CYP2C11 mRNA and protein expression is suppressed by LPS, IL-1, or by a cocktail of cytokines including LPS, IL-1, tumor necrosis factor-α, and interferon-γ (Sewer and Morgan, 1997). This is accompanied by a large stimulation of NO production by the cells. The competitive NOS inhibitor N-monomethyl-l-arginine completely blocked the induced production of NO but failed to affect the downregulation of CYP2C11 mRNA or protein by any of these stimuli at any time point measured (Sewer and Morgan, 1997). We concluded that NO is not required for CYP2C11 downregulation by IL-1 or LPS in cultured hepatocytes.

To study the role of NO in P450 downregulation in rats in vivo, we treated rats with LPS and aminoguanidine, a somewhat selective inhibitor of NOS2. Injections of aminoguanidine every 4 hr completely prevented the rise in plasma NO oxidation products by LPS. Despite this fact, aminoguanidine injections every 4 hr had no effect on the downregulation of CYP2C11, CYP3A2, or CYP2E1 mRNAs or proteins by LPS treatment (Sewer and Morgan, 1998). An interesting aspect of this work was that we observed a decrease in CYP2C11 catalytic activity only 6 hr after LPS treatment when CYP2C11 protein levels were the same as in control livers. One could speculate that this effect is due to inhibition of CYP2C11 catalytic activity by NO, but the aminoguanidine+LPS–treated animals were not informative because aminoguanidine alone caused a decrease in CYP2C11 activity at this time point (Sewer and Morgan, 1998).

Two possible explanations for the lack of agreement between our studies and those of others using NOS inhibitors are (a) that NOS inhibitors have nonspecific effects, or (b) that they may not completely inhibit NO synthesis even when there is no detectable (nitrate + nitrite) in the plasma or culture media. To eliminate both of these concerns, we examined the downregulation of P450 expression and activity in NOS2 knockout mice. These mice are B6,129 hybrids whose NOS2 gene has been disrupted in the calmodulin binding domain, resulting in a frameshift and no detectable NOS2 protein (Laubach et al., 1995). The disruption causes no overt phenotype, but stimulated macrophages from the homozygous knockout (−/−) animals fail to produce NO, and there is no elevation of NO in the plasma in response to LPS injection.

When the parental B6,129 mice (+/+) were injected with LPS, there was a 50% (approximately) decrease in microsomal levels of CYP3A, CYP2C, and CYP2E proteins measured 24 hr after injection by Western blotting with antibodies to rat CYP3A2, CYP2C11, and CYP2E1 (fig.1; Sewer et al., 1998). The mRNAs for CYP3A11 and CYP2C29 were also suppressed by about the same magnitude (Sewer et al., 1998). NOS2 −/− mice showed the same changes in these parameters as did the +/+ animals, indicating that NO is not required for downregulation of these P450s during endotoxemia (Sewer et al., 1998).

Figure 1
Figure 1

Downregulation of P450 proteins in NOS2 knockout mice.

Male B6,129 (+/+) or NOS2 knockout (B6,129-NOS2, −/−) mice were injected with saline or 1 mg Escherichia coli LPS per kg body weight, and hepatic microsomal protein was isolated 24 hr later. Equal amounts of protein were subjected to Western blot analysis using antibodies to rat P450 2C11, 2E1, and 3A2, respectively. The graph shows results from densitometric analysis of the blots, with five mice per treatment group (means ± SE). Results are expressed as a percentage of the saline-treated group mean. *, Significantly different from saline-treated mice, p < 0.05. The data are adapted from Sewer et al. (1998).

To determine whether NO could be involved in the inhibition of P450 catalytic activity early in the response to LPS (when P450 protein levels are unaffected), we compared the testosterone hydroxylase activities of microsomes from +/+ and −/− mice 6 hr after injection of saline or LPS. At this time point, LPS caused decreases in the 6β- and 16β-testosterone hydroxylase activities of the microsomes, whereas the 15α- and 16α-hydroxylase activities were unaffected. In contrast, testosterone 7α-hydroxylase activity was actually increased slightly. In the NOS2 knockout mice, there was no significant decrease in testosterone 6β- or 16β-testosterone hydroxylase activities, suggesting that NO could be partially responsible for the LPS-evoked declines in these activities at 6 hr (Sewer et al., 1998). However, this is not a firm conclusion because the lack of a significant effect on 6β- and 16β-hydroxylase activities in the −/− mice could have been due to the observed decrease in basal activity or the large variability in the control group activities (Sewer et al., 1998), respectively. Of course, the measurement of P450 activities in isolated microsomes would not be expected to detect a reversible inhibition of P450 activity caused by heme coordination of the NO (Wink et al., 1993).

In conclusion, our results indicate that NO is not required for the inflammatory downregulation of the mRNA or protein levels of CYP2C11, CYP3A2, or CYP2E1 in the rat or CYP2C29, CYP3A11, or CYP2E1 in the mouse. The possibility remains that NO liberated during inflammation could inhibit P450 catalytic activity in vivo independently of an effect on gene regulation.

Conditional Gene Disruption for the Study of Transcription Factors and Regulation of Genes Encoding Xenobiotic-Metabolizing Enzymes (F.J.G., Y.-H.L.)

Most genes encoding xenobiotic-metabolizing enzymes are constitutively expressed in the liver and under control of families of liver-enriched transcription factors, including HNF-1, HNF-3, HNF-4, rat albumin gene D region binding protein, and C/EBP (Cereghini, 1996). Some of these genes are also controlled by ligand-activated receptors, including the aryl hydrocarbon (Ah) receptor and peroxisome proliferator-activated receptor α. Historically, regulation of gene expression has been studied using in vitro DNA binding and transfection studies with reporter gene constructs and recombinant transcription factors. These experiments have been used to determine the presence of cis-acting regulatory elements andtrans-acting factors associated with specific genes. In many cases, several cis-acting elements andtrans-acting factors were found to be involved with regulation of certain genes specifically expressed in the liver. For example, the α-fetoprotein gene is expressed in the liver, and its transcription is tightly regulated during the course of development and hepatocarcinogenesis (Bois-Joyeux et al., 1995). Studies have shown that the α-fetoprotein gene has binding sites for the family of C/EBP factors, HNF-1α and NF-1. The albumin gene also binds to multiple transcription factors, including the C/EBPs, rat albumin gene D region binding protein, NF1, NFY, and HNF-1 (Troncheet al., 1990), and all of these factors can modulate transcriptional activity as assessed by in vitrotranscription and transfection studies. However, it is not clear whether all of these transcription factors are actually functional in the intact animal or whether a single factor predominates in the adult. This question can be addressed using targeted gene disruption, in which expression of a specific transcription factor can be extinguished.

The standard gene-targeting strategy has been used to disrupt genes encoding transcription factors; however, in many cases the mutations were found to result in embryonic or early postnatal lethality. For example, embryonic lethality was found after disruption of the genes encoding ARNT (Maltepe et al.,1997) and hypoxia-inducible factor 1α (Iyer et al., 1998), two members of the per and sim/beta helix-loop-helix receptor gene superfamily that includes the Ah receptor (Rowlands and Gustafsson, 1997). Knockout of genes encoding hepatocyte-enriched transcription factors, including HNF-4 (Duncan et al., 1997), HNF-1 (Pontoglio et al., 1996), and C/EBPα (Wang et al., 1995) results in embryonic arrest or early postnatal lethality, indicating that in addition to their regulatory roles in tissue-specific expression of hepatic genes, these factors are critical for embryogenesis and development. Accordingly, it is impossible to study the in vivoregulation of gene expression and physiological functions of many transcription factors in adult mice since lethality occurs before the onset of expression of genes encoding xenobiotic-metabolizing enzymes in the mature animal.

To avoid disrupting genes at the germ cell level, using the traditional gene knockout technique, the Cre/loxP conditional gene targeting system (Schwenk et al., 1998; Torres and Kuhn, 1997) was utilized to disrupt genes encoding several liver-enriched transcription factors in a tissue- and age-dependent manner to study their effects on expression of xenobiotic-metabolizing enzymes in the liver. Cre is a bacteriophage DNA recombinase that can delete or invert DNA segments flanked by two loxP sites containing the recognition sequence for the Cre recombinase. LoxP sites were inserted into several liver-enriched transcription factor genes by using the standard genetargeting technique in embryonic stem cells. These small pieces of DNA are not expected to disrupt gene expression. Cre can be delivered to the liver either by use of recombinant adenovirus (AdCre) or by transgenic mouse lines in which the Cre transgene is driven by an inducible gene promoter that can be activated in the liver at any stage of development (fig. 1). The Cre/loxP conditional gene targeting system was used to study the physiological functions of C/EBPα (Lee et al.,1997) and HNF-1α (Lee et al., 1998) and their roles in regulating liver-specific expression of genes encoding xenobiotic-metabolizing enzymes.

The C/EBPα gene was disrupted by use of the Cre/loxP system (Leeet al., 1997). The whole C/EBPα gene was flanked by loxP sites and used to generate a homozygous C/EBPα-floxed mouse line. The “floxed” mice were injected through the tail vein with AdCre. This route of injection primarily results in infection of hepatocytes. Several days after injection of the virus, the liver was analyzed by Southern blotting, and the C/EBPα gene was found to be deleted in >90% of the liver DNA. No significant deletion was detected in the lung or kidney, indicating that the virus specifically targeted the liver. Expression of C/EBPα mRNA was also found to be reduced by >90%, while levels of mRNA encoding albumin and β-actin were not different between the C/EBPα conditional-null mice and wild-type mice (fig. 2). However, expression of a form of UDP-glucuronosyltransferase (UGT) designated UGT2B1 mRNA was markedly reduced. In contrast, expression of this gene was not different between the C/EBPβ-null mouse and wild-type mice. This result was quite surprising since C/EBPα and C/EBPβ bind to the same recognition sequence and activate many of the same promoters intrans-activation transfection assays.

Figure 2
Figure 2

Schematic diagram of the Cre/loxP conditional gene knockout system.

LoxP sites (♦) are incorporated into the cloned gene. In the diagram, the loxP sites are flanking the gene. Homozygous floxed mice are produced by targeting the modified allele by using the standard method of targeting embryonic stem cells followed by production of mice. Since the small loxP sites are placed in non-essential regions of the gene, gene expression is normal. The Cre gene can be introduced either through a viral vector or by use of a transgenic mouse in which the Cre gene is driven by an inducible promoter (IP). When an inducer is added, it results in expression of Cre and recombination to delete the target gene. The Cre can also be delivered using AdCre.

The C/EBPα conditional-null mice were also found to have high levels of serum bilirubin, indicating a defect in bilirubin conjugation. Typically, bilirubin is conjugated, and the conjugate is eliminated through the bile. In genetic deficiencies in bilirubin conjugation, UGT1*6, the UGT form responsible for bilirubin conjugation, is reduced or eliminated, resulting in high levels of serum bilirubin and the typical yellow-skin jaundiced phenotype (Mackenzie et al., 1997; Owens and Ritter, 1995). The UGT1*6 mRNA was found to be markedly reduced in the C/EBPα-floxed mouse line injected with AdCre (fig. 3), indicating that C/EBPα is required for constitutive expression of the UGT1*6 gene. It is noteworthy that these are the first studies establishing the role of specific transcription factors in control of members of both the UGT1 and UGT2 gene families. These studies established that C/EBPα is responsible for liver-specific expression of xenobiotic-metabolizing and bilirubin-conjugating genes.

Figure 3
Figure 3

Northern blot analysis of various mRNAs in the livers of adult C/EBPα conditional knockout and C/EBPβ knockout mice.

The cDNA probes used are listed. fl represents the floxed C/EBPα allele.

The HNF-1α gene was also subjected to gene knockout studies (Leeet al., 1998). When an HNF-1α gene was made by use of the Cre/loxP system, in which the gene was disrupted in the germ cell stage by using the adenovirus EIIa-Cre transgenic mouse instead of in the adult mouse (Lakso et al. 1996), the mice obtained were viable and lived to maturity. This is in contrast to the HNF-1α-null mice developed earlier using the standard gene-targeting strategy, which results in early postnatal lethality (Pontoglio etal., 1996). The mice developed using the Cre/loxP method had no signs of kidney disease and did not die early after birth (Leeet al., 1998). These mice were runty, diabetic, and sterile due in part to low levels of growth hormone and high levels of insulin-like growth factor II and a deficiency in pancreatic insulin production. These phenotypes were not detected in the earlier HNF-1α-null mice because of premature death due in part to a kidney disorder. It remains unclear why the phenotypes of the two embryonic knockout mice differ, but it was suggested that the presence of the phosphoribosyltransferase II (Neo cassette) gene and the β-galactosidase gene in the targeted allele of the earlier mouse line (Pontoglio et al., 1996) caused additional phenotypes that are not directly due to loss of HNF-1α (Lee et al., 1998). The Cre/loxP method results in removal of the Neo cassette that is used in preparation and selection of targeted embryonic stem cells. The HNF-1α-null mice were examined for expression of P450 genes. Earlier studies have indicated that this factor is involved in regulation of CYP2E1 (Liu and Gonzalez, 1995) and CYP1A2 (Chung and Bresnick, 1997). Indeed mRNA derived from both of these genes were found to be downregulated in the HNF-1α-null mice (unpublished results). These results establish the utility of using gene knockout mice to study gene regulation in vivo.

The Role of Signal Transduction and Ah Receptor–Mediated Transcriptional Activation of the CYP1A1 Gene (R.H.T., S.O., T.V., Y.-H.C.)

The dioxin or aryl hydrocarbon (Ah) receptor is a nuclear transcriptional factor that controls the expression of a host of different genes whose functions are linked to the metabolism of dietary constituents, drugs and potentially hazardous agents through exposure to environmental contaminants. Several of the enzymes involved in this process include a number of the heme-thiolate proteins (cytochrome P450s) (Tukey et al., 1981; Okino et al., 1992), the rodent UDP-glucuronosyltransferase identified as UGT1A6 (Lamb et al., 1994; Iyanagi et al., 1986), the NAD(P)H:quinone oxidoreductases (Jaiswal, 1991) and several of the glutathione S-transferases (Telakowski-Hopkins et al., 1988; Pimental et al., 1993). These enzymes are located in abundance in tissues that play an important role in first-pass metabolism, digestion, and drug metabolism, such as those of the gastrointestinal tract and the liver. Regulation of gene expression by the Ah receptor results in the induction of proteins involved in both Phase I and Phase II drug metabolism, a process that facilitates the channeling of hydrophilic substances to more polar oxidized compounds, as well as the processing of agents through conjugation reactions to water-soluble metabolites. For the most part, these enzymatic reactions could be considered to play an important role in drug metabolism by targeting these compounds for elimination since the result of metabolism is a substantial increase in the partition coefficient of these agents for water. However, the induction of certain heme-thiolate proteins, such as CYP1A1, is considered to be potentially counterproductive to this process since CYP1A1 is capable of producing epoxides and dihydrodiol epoxides from aromatic and halogenated hydrocarbons. These metabolites have been shown in a number of experimental systems to be mutagenic (McManus et al., 1990). Therefore, it is important to understand the cellular and molecular processes that contribute to the induction of gene expression after activation of the Ah receptor. As a result of the significant levels of induction of the CYP1A1 gene, an appreciation of the regulatory potential of the Ah receptor has been obtained through experiments examining the ability of the receptor to activateCYP1A1 transcription.

An understanding of the cellular signaling events involved in the activation of the Ah receptor, a process that stimulates its nuclear uptake and dimerization with ARNT, has been eloquently elucidated by several researchers (Gradin et al., 1994; Jainet al., 1994; Fujisawa-Sehara et al., 1987;Pollenz et al., 1994; Okino and Whitlock, 1995; Reyeset al., 1992). A general flow diagram of some of these events is shown in fig. 4. The activation of the Ah receptor by ligand is coupled with the release of hsp90, a process that is linked to tyrosine kinase activity. Ligand association is followed by rapid uptake of liganded complex into the nucleus (Tukey et al., 1982), where it pairs with the nuclear ARNT protein (Whitelaw et al., 1993). In mice, the intraperitoneal administration of 3-methylcholanthrene has been shown to fully simulate nuclear uptake in less than 30 min, as measured by EMSA (Pendurthi et al., 1993). Similar studies have detected the Ah receptor in the nucleus as early as 5 min after exposure of HepG2 cells to TCDD. While this is certainly an active transport process, there is very little known about the cellular events that underlie nuclear uptake of the Ah receptor.

Figure 4
Figure 4

Flow diagram showing the potential involvement of PKC in the regulation of CYP1A1 gene transcription and Ah receptor regulation.

PKC is regulated by Ah receptor ligands, humoral factors, and cellular calcium, which influences Ah receptor uptake to the nucleus as well CYP1A1 gene transcription. The mechanisms of action of PKC on transcription and Ah receptor uptake are unknown but could potentially involve Jun kinase (JNKinase), AP-1 (Fos/Jun), as well as phosphorylation events that might impact directly on the assembly of proteins that promote transcription. Ligand binding to the Ah receptor involves hsp90 and tyrosine kinase (PKA), and there is evidence that PKA may also effect transcriptional events.

The treatment of mice by the intraperitoneal administration of phorbol esters such as TPA dramatically reduced the TCDD directed transcriptional activation of the Cyp1a1 gene (Okinoet al., 1992). Analysis of Ah receptor activation and nuclear binding to enhancer sequences indicated that the reduction in TCDD-initiated Cyp1a1 transcriptional activity by TPA was in part attributed to a reduction in nuclear migration of the Ah receptor to the nucleus. This was documented directly by following the uptake and migration of 3H-TCDD–receptor complex from the cytosol to nucleus, a result that confirmed that the actions of TPA were interfering with nuclear transport processes. Since one of the actions of TPA results in the stimulation of PKC, an early event in many of the signaling events, experiments were undertaken to examine the actions of PKC on CYP1A1 transcription.

A clonal HepG2 cell, called 101L, was developed, which carries theCYP1A1 regulatory and promoter elements driving the firefly luciferase gene (Postlind et al., 1992). With the ease of analyzing luciferase activity, the cells serve as an ideal biological tool for analysis of Ah receptor agonists as determined by transcriptional activation of the reporter gene. Ah receptor ligands such as TCDD, 3MC, polychlorinated biphenyls, and benzodiazipines activate CYP1A1 luciferase activity (Quattrochi and Tukey, 1993; Chen and Tukey, 1996). Dose-dependent increases in transcriptional activity appear to be concordant with the accumulation of the Ah receptor in the nucleus, as measured by EMSA. To examine the effect of PKC activation on CYP1A1 transcription, 101L cells were treated with several receptor ligands in the presence of TPA. While Ah receptor agonists induced CYP1A1transcription, phorbol esters increased transcriptional activity two- to threefold (fig. 5). The ability of PMA to synergize TCDD-mediated induction is an early event, since longer-term exposure of cells to PMA leads to a reduction in this response. Interestingly, the actions of PMA appear to facilitate the accumulation of Ah receptor in the nucleus with longer exposure times, as measured by EMSA, but this increase is not concordant with enhanced transcriptional events. The early synergistic actions of PMA are specific since 4α-phorbol 12,13-didecanoate, an inactive phorbol ester derivative, showed no effect on TCDD-induced transcriptional activation. Combined, the direct actions of PMA on HepG2 cells indicate that PKC activity plays a role in both the nuclear transport as well as in the ligand-induced actions of the Ah receptor on CYP1gene transcription.

Figure 5
Figure 5

The actions of phorbol esters onCYP1A1 gene transcription.

101L cells were treated with phorbol 12-myristate 13-acetate (PMA) for either 3, 24, 48 or 72 hr, followed by 3 hr with TCDD. Electrophoretic mobility shift analysis (EMSA) using oligonucleotides to the DRE sequence are shown in the upper panel. The effects of TCDD and PMA on CYP1A1 transcription are shown in the lower panel.

The specific activation of transcription by PKC activity elicited by phorbol esters could be monitored by treating cells with PKC-specific inhibitors such as staurosporine and chelerythrine chloride. Interestingly, PKC inhibitors not only abrogated the synergistic actions of PMA on CYP1A1 transcriptional activity, but they also completely abolished Ah receptor ligand–mediated induction of reporter gene activity. In the experiment shown in fig.6, 1 nM TCDD can generate a 40-fold increase in luciferase activity within 3 hr. Thirty minutes’ pre-treatment with PKC inhibitors blocks TCDD induction. The induction of HepG2 CYP1A1 mRNA by TCDD is also blocked when cells are treated with PKC inhibitors (not shown). The rapid inhibition ofCYP1A1 gene transcription in the presence of PKC inhibitors suggests that cellular PKC activity plays an important role in the functional properties of the Ah receptor or the catalytic mechanisms that underlie CYP1A1 transcription.

Figure 6
Figure 6

Effects of PKC inhibitors on CYP1A1 gene transcription. 101L cells were pretreated with staurosporine (ST) or chelerythrine chloride (ChCl) for 1 hr, followed by the addition of 1nM TCDD and/or 125 nM PMA for 3 hr. After incubation, the cells were harvested and luciferase activity was determined. DMSO, dimethyl sulfoxide; RLU, relative light units.

The role of PKC could not be directly linked to the functional properties of the Ah receptor. Treatment of 101L cells with PKC inhibitors did not affect the ability of TCDD to bind to the cytosolic Ah receptor or to activate a cytosolic receptor into a DNA-binding form. In addition, TCDD-initiated uptake of the Ah receptor to the nucleus, as determined by the ability of the activated nuclear receptor to bind to xenobiotic response element sequences, was not altered by pretreatment of HepG2 cells with PKC inhibitors. While PKC has been shown to promote the nuclear accumulation of Ah receptor, its actions appear to be secondary to additional signals that promote the ligand-induced uptake of the receptor. While PKC inhibitors efficiently block ligand-mediated induction of CYP1A1 gene transcription, the inability of these inhibitors to impact on the functional properties of the Ah receptor (i.e. ligand binding, nuclear uptake, activation to a DNA-binding form) indicates that PKC activity is involved in cellular or molecular events that play a crucial role in facilitating the ability of the receptor to promote transcription. It is unclear whether PKC activity or additional signaling mechanisms utilize the Ah receptor as substrate or whether its actions are more general in nature by supporting the transactivation potential of the receptor. The latter would appear to be the case, since PKC inhibition blocks transactivation of reporter genes by ARNT as well as by TCDD-directed induction of reporter genes by the Ah receptor.

In summary, the potential role of cellular signaling pathways on the regulation and control of the CYP1A1 gene are outlined in fig. 4. Cellular mechanisms that modulate PKC activity have been demonstrated to influence the nuclear uptake of the Ah receptor as well as control the ability of the receptor to promote transcriptional activation of the CYP1A1 gene (Chen and Tukey, 1996;Berghard et al. 1993; Carrier et al., 1992). While exposing rodents to phorbol esters impairs Ah receptor uptake to the nucleus and a reduction in transcriptional activation of theCyp1a genes, phorbol esters dramatically stimulate Ah receptor–mediated transcriptional activation of the CYP1A1gene in HepG2 cells. This contradiction in response could be attributed to the role or activation by TPA of humoral factors in vivothat are not present in an isolated cell system, which in turn influence cellular signaling processes that cannot be duplicated in tissue culture. The accelerated rate of CYP1A1 transcription in HepG2 cells and this linkage to PKC activity most likely involves cellular signaling events that do not dramatically influence Ah receptor activation or function. It is certainly possible that PKC could be initiating signals through phosphorylation patterns that impact on the assembly of the transcriptional complex, a priority that may be necessary for protein-protein interactions between the Ah receptor and other transcriptional factors. Since it has been shown that Ah receptor ligands are capable of activating PKC (Weber et al., 1994; Bombick et al., 1985), ligand-induced activation of the Ah receptor, as well as the promotion of PKC-directed signaling events, may occur in concert to promote the molecular changes necessary to stimulate CYP1A1 gene transcription.

Signaling and Receptor Pathways Modulating Gene Induction by Phenobarbital (J.S.S., C.J.O.)

Phenobarbital (PB) is a prototype agent for other barbiturates and a variety of other xenobiotic compounds such as chlordane, dichlorodiphenyl-trichloroethane, certain polychlorinated biphenyls,etc., that exhibit profound inductive effects on a variety of biotransformation systems, including particular glutathione-S-epoxide transferases, UDP-glucuronyl transferases, aldehyde dehydrogenases, and the cytochrome P450 monooxygenases (Honkakoski and Negishi, 1998; Waxman and Aronoff, 1992). The PB induction response occurs in many species, including humans (Waxman and Aronoff, 1992).

Although it was demonstrated previously that PB stimulates these genes at the transcriptional level (Hardwick et al., 1983), relatively little is known regarding the underlying molecular mechanisms governing the PB induction response or cell- or stage-specific expression of P450 genes. Previous reports from our laboratory (Omiecinski, 1986), and many others (Wojcik et al., 1988; Bars et al., 1992) have established that the liver is a primary PB-responsive organ in mammalian organisms.

A 15-bp “barbie box” promoter element was characterized as an important regulator of PB induction in Bacillus megaterium(He and Fulco, 1991; Shaw and Fulco, 1993); however, an accumulating body of evidence now suggests that critical regulatory elements for PB induction in mammalian liver cells exist independently of the barbie box (Shaw et al., 1998). Studies using gene-transfection analyses in primary rat and mouse hepatocytes (Stoltz et al., 1998; Honkakoski et al., 1998) and direct gene injections in rat liver (Park et al., 1996) demonstrated that proximal promoter barbie box sequences were not required for PB responsiveness in these systems. Rather, experimental results have implicated a PB-responsive unit (PBRU) upstream of the barbie box element as modulating PB activation. Anderson and co-workers delineated a PBRU from −2318 bp to −2155 bp upstream of the transcription start site of the CYP2B2 gene (Trottier et al., 1995; Stoltz et al., 1998). In the mouse Cyp2b10gene, a region from −2170 to −2258 bp was identified by functional studies as conferring PB responsiveness (Honkakoski and Negishi, 1997) and was more recently narrowed to a 51-bp element centering on an NF-1 site (Honkakoski and Negishi, 1998). Of interest, this 51-bp region also contains putative half-sites for nuclear receptors (Honkakoski and Negishi, 1998). In another recent study,in vivo footprinting approaches were used to define PB-induced chromatin alterations in the −2.2 kb region of the ratCYP2B1/2 genes, also centering around a putative NF-1 site (Kim and Kemper, 1997). This positioning of a PB-responsive region is consistent with functional experiments we reported previously, which used transgenic mouse lines that demonstrated that gene sequences residing 5′ of −800 bp upstream of the transcription initiation site were required for PB-inducible expression of CYP2B2 (Ramsdenet al., 1993).

For some years it has been assumed that PB induction required de novo protein synthesis. However, evidence we had accumulated that indicated that post-transcriptional processes, i.e. protein kinase/ phosphatase cascades, are regulators of PB signaling in hepatocytes did not appear to be consistent with these perceptions (Sidhu and Omiecinski, 1995 and 1997). These studies, which examined the role of cAMP/PKA activators and PP1/PP2A inhibitors on the PB signaling process, indicated that an upstream phosphatase pathway may participate as an activator of PB induction (Sidhu and Omiecinski, 1995and 1997). Furthermore, results from DNase I hypersensitivity determinations, DNA affinity purification experiments, electrophoretic mobility shift assays, and in vitro DNase I footprinting studies all failed to reveal differences between nuclear protein extracts derived from control or PB-induced liver (Stoltz et al., 1998; Sommer et al., 1996). In a recent study, we demonstrated that de novo protein synthesis was not required for PB induction (Sidhu and Omiecinski, 1998). Although certain protein synthesis inhibitors did inhibit the response, the latter effect appeared to be non-specific since inactive analogs of protein synthesis inhibitors, e.g. puromycin aminonucleoside, also were potent negative modulators of PB induction. Other pathways are perturbed in hepatocytes by application of a variety of protein synthesis inhibitors, including the stress-activated protein kinase cascade (Sidhu and Omiecinski, 1998). Therefore, in view of the collective data, it appears likely that pre-existing regulatory factors interact with the PBRU constitutively and then are subjected to post-transcriptional alterations in the presence of PB. These alterations in turn may enable positive interaction of the PBRU with the transcriptional initiation complex.

A broad array of pharmacological agents effective in modulating various cell-signaling pathways have been tested in our laboratory for their effects on the PB-induction process. Examples are illustrated in table1. The data illustrate the caution that needs to be exercised before deriving conclusions from effects of “specific” modulators. For example, we observed that staurosporine, a broad-band kinase inhibitor that has been used by investigators as a “specific” PKC inhibitor, profoundly inhibited the PB-induction response in cultured hepatocytes. Similar effects were noted with KN64, an inhibitor of Ca2+ calmodulin kinase II. However, when additional modulators of the same pathways were tested, contrasting results were obtained. Use of inactive structural analogs of the specific effector agents has provided an important resource for dissecting the actual effects. With these agents, we have demonstrated that, contrary to initial indications, neither the PKC nor Ca2+ calmodulin kinase II pathways appear to be involved in PB signaling. The lack of effect of the specific mitogen-activated protein kinase kinase inhibitor, PD 98059, also appears to rule out the mitogen-activated protein kinase pathway as integral to PB signaling. Further experiments are in progress to delineate the exact nature of the PB-signaling response. It is likely that the downstream targets of these pathways will impinge on the nuclear regulatory proteins interacting with the PBRU and basal transcriptional machinery.

View this table:
Table 1

Summary of effects of various pharmacological agents and analogs on PB induction in primary rat hepatocyte cultures1-a

Footnotes

  • Send reprint requests to: Edward T. Morgan, Ph.D., Department of Pharmacology, Emory University, Atlanta, GA 30322. e-mail:etmorga{at}emory.edu

  • This work was supported by grants GM46897 (E.T.M.), GM53093 (E.T.M.) T32DK07298 (H.I.) GM36590 (R.H.T.) GM32281 (C.J.O.) and Center Grant ES07033 (C.J.O.) from the National Institutes of Health. M.B.S. was supported by a Predoctoral fellowship from the Howard Hughes Medical Institute. C.J.O. is a Burroughs Wellcome Toxicology Scholar.

  • Abbreviations used are::
    AdCre
    recombinant adenovirus containing the Cre gene
    Ah
    aryl hydrocarbon
    ARNT
    Ah receptor nuclear translocator
    C/EBP
    CAAT enhancer-binding protein
    Cre
    Cre recombinase
    EMSA
    electrophoretic mobility shift assay
    HNF
    hepatocyte nuclear factor
    IL
    interleukin
    LPS
    bacterial lipopolysaccharide
    NF
    nuclear factor
    NF-1
    nuclear factor 1
    P450
    cytochrome P450
    NOS2
    inducible nitric oxide synthase
    PB
    phenobarbital
    PBRU
    phenobarbital responsive unit
    PKA
    cAMP-activated protein kinase
    PKC
    protein kinase C
    PP
    protein phosphatase
    TCDD
    2,3,7,8-tetrachlorodibenzo-p-dioxin
    TPA
    tetradecanoyl phorbol acetate
    UDP
    uridine diphosphate
    UGT
    UDPglucuronosyltransferase

References

  1. ↵
    1. Bars RG,
    2. Bell DR,
    3. Elcombe CR,
    4. Oinonen T,
    5. Jalava T,
    6. Lindros KO
    (1992) Zone-specific inducibility of cytochrome P450 2B1/2 is retained in isolated perivenous hepatocytes. Biochem J 282:635–638.
  2. ↵
    1. Berghard A,
    2. Gradin K,
    3. Pongratz I,
    4. Whitelaw M,
    5. Poellinger L
    (1993) Cross-coupling of signal transduction pathways: The dioxin receptor mediates induction of cytochrome P-450IA1 expression via a protein kinase C-dependent mechanism. Mol Cell Biol 13:677–689.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Bernton EW,
    2. Beach JE,
    3. Holaday JW,
    4. Smallridge RC,
    5. Fein HG
    (1987) Release of multiple hormones by a direct action of interleukin-1 on pituitary cells. Science 238:519–521.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Bois-Joyeux B,
    2. Thomassin H,
    3. Richard F,
    4. Ikonomova R,
    5. Denissenko M,
    6. Danan JL
    (1995) [Several transcription factors participate in the functioning of the alpha-fetoprotein gene promoter.] Bull Cancer 82:541–550, In French..
    OpenUrlPubMed
  5. ↵
    1. Bombick DW,
    2. Madhukar BV,
    3. Brewster DW,
    4. Matsumura F
    (1985) TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin) causes increases in protein kinases particularly protein kinase C in the hepatic plasma membrane of the rat and the guinea pig. Biochem Biophys Res Commun 127:296–302.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Carlson TJ,
    2. Billings RE
    (1996) Role of nitric oxide in the cytokine-mediated regulation of cytochrome P-450. Mol Pharmacol 49:796–801.
    OpenUrlAbstract
  7. ↵
    1. Carrier F,
    2. Owens RA,
    3. Nebert DW,
    4. Puga A
    (1992) Dioxin-dependent activation of murine Cyp1a-1 gene transcription requires protein kinase C-dependent phosphorylation. Mol Cell Biol 12:1856–1863.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Cereghini S
    (1996) Liver-enriched transcription factors and hepatocyte differentiation. FASEB J 10:267–282.
    OpenUrlAbstract
  9. ↵
    1. Chen Y,
    2. Tukey RH
    (1996) Protein kinase C modulates regulation of the CYP1A1 gene by the Ah receptor. J Biol Chem 271:26261–26266.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Chung I,
    2. Bresnick E
    (1997) Identification of positive and negative regulatory elements of the human cytochrome P4501A2 (CYP1A2) gene. Arch Biochem Biophys 338:220–226.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Donahue BS,
    2. Skottner-Lundin A,
    3. Morgan ET
    (1991) Growth hormone–dependent and –independent regulation of cytochrome P-450 isozyme expression in streptozotocin-diabetic rats. Endocrinology 128:2065–2076.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Duncan SA,
    2. Nagy A,
    3. Chan W
    (1997) Murine gastrulation requires HNF-4 regulated gene expression in the visceral endoderm: tetraploid rescue of Hnf-4(−/−) embryos. Development 124:279–287.
    OpenUrlAbstract
  13. ↵
    1. Favreau L,
    2. Schenkman JB
    (1988) Composition changes in hepatic microsomal cytochrome P-450 during onset of streptozotocin-induced diabetes and during insulin treatment. Diabetes 37:577–584.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Fujisawa-Sehara A,
    2. Sogawa K,
    3. Yamane M,
    4. Fujii-Kuriyama Y
    (1987) Characterization of xenobiotic responsive elements upstream from the drug-metabolizing cytochrome P-450c gene: A similarity to glucocorticoid regulatory elements. Nucleic Acids Res 15:4179–4191.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Gradin K,
    2. Whitelaw ML,
    3. Toftgård R,
    4. Poellinger L,
    5. Berghard A
    (1994) A tyrosine kinase-dependent pathway regulates ligand-dependent activation of the dioxin receptor in human keratinocytes. J Biol Chem 269:23800–23807.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Hardwick JP,
    2. Gonzalez FJ,
    3. Kasper CB
    (1983) Transcriptional regulation of rat liver epoxide hydratase, NADPH-Cytochrome P-450 oxidoreductase, and cytochrome P-450b genes by phenobarbital. J Biol Chem 258:8081–8085.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. He JS,
    2. Fulco AJ
    (1991) A barbiturate-regulated protein binding to a common sequence in the cytochrome P450 genes of rodents and bacteria. J Biol Chem 266:7864–7869.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Honkakoski P,
    2. Moore R,
    3. Washburn KA,
    4. Negishi M
    (1998) Activation by diverse xenochemicals of the 51-base pair phenobarbital-responsive enhancer module in the CYP2B10 gene. Mol Pharmacol 53:597–601.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Honkakoski P,
    2. Negishi M
    (1997) Characterization of a phenobarbital-responsive enhancer module in mouse P450 Cyp2b10 gene. J Biol Chem 272:14943–14949.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Honkakoski P,
    2. Negishi M
    (1998) Regulatory DNA elements of phenobarbital-responsive cytochrome P450 CYP2B genes. J Biochem Mol Toxicol 12:3–9.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Iyanagi T,
    2. Haniu M,
    3. Sogawa K,
    4. Fujii-Kuriyama Y,
    5. Watanabe S,
    6. Shively JE,
    7. Anan KF
    (1986) Cloning and characterization of cDNA encoding 3-methylcholanthrene inducible rat mRNA for UDP-glucuronosyltransferase. J Biol Chem 261:15607–15614.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Iyer NV,
    2. Kotch LE,
    3. Agani F,
    4. Leung SW,
    5. Laughner E,
    6. Wenger RH,
    7. Gassmann M,
    8. Gearhart JD,
    9. Lawler AM,
    10. Yu AY,
    11. Semenza GL
    (1998) Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes & Dev 12:149–162.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Jain S,
    2. Dolwick KM,
    3. Schmidt JV,
    4. Bradfield CA
    (1994) Potent transactivation domains of the Ah receptor and the Ah receptor nuclear translocator map to their carboxyl termini. J Biol Chem 269:31518–31524.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Jaiswal AK
    (1991) Human NAD(P)H:quinone oxidoreductase (NQO1) gene structure and induction by dioxin. Biochemistry 30:10647–10653.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Khatsenko O,
    2. Kikkawa Y
    (1997) Nitric oxide differentially affects constitutive cytochrome P450 isoforms in rat liver. J Pharmacol Exp Ther 280:1463–1470.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Kim J,
    2. Kemper B
    (1997) Phenobarbital alters protein binding to the CYP2B1/2 phenobarbital-responsive unit in native chromatin. J Biol Chem 272:29423–29425.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Lakso M,
    2. Pichel JG,
    3. Gorman JR,
    4. Sauer B,
    5. Okamoto Y,
    6. Lee E,
    7. Alt FW,
    8. Westphal H
    (1996) Efficient in vivo manipulation of mouse genomic sequences at the zygote stage. Proc Natl Acad Sci USA 93:5860–5865.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Lamb JG,
    2. Straub P,
    3. Tukey RH
    (1994) Cloning and characterization of cDNAs encoding mouse Ugt1.6 and rabbit UGT1.6: Differential induction by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Biochemistry 33:10513–10520.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Laubach VE,
    2. Shesely EG,
    3. Smithies O,
    4. Sherman PA
    (1995) Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death. Proc Natl Acad Sci USA 92:10688–10692.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Lee YH,
    2. Sauer B,
    3. Gonzalez FJ
    (1998) Laron dwarfism and non-insulin-dependent diabetes mellitus in the Hnf-1alpha knockout mouse. Mol Cell Biol 18:3059–3068.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    1. Lee YH,
    2. Sauer B,
    3. Johnson PF,
    4. Gonzalez FJ
    (1997) Disruption of the c/ebp alpha gene in adult mouse liver. Mol Cell Biol 17:6014–6022.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Liu SY,
    2. Gonzalez FJ
    (1995) Role of the liver-enriched transcription factor HNF-1 alpha in expression of the CYP2E1 gene. DNA Cell Biol 14:285–293.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Ma Q,
    2. Dannan GA,
    3. Guengerich FP,
    4. Yang CS
    (1989) Similarities and differences in the regulation of hepatic cytochrome P-450 enzymes by diabetes and fasting in male rats. Biochem Pharmacol 38:3179–3184.
    OpenUrlCrossRefPubMed
  34. ↵
    1. Mackenzie PI,
    2. Owens IS,
    3. Burchell B,
    4. Bock KW,
    5. Bairoch A,
    6. Belanger A,
    7. Fournel-Gigleux S,
    8. Green M,
    9. Hum DW,
    10. Iyanagi T,
    11. Lancet D,
    12. Louisot P,
    13. Magdalou J,
    14. Chowdhury JR,
    15. Ritter JK,
    16. Schachter H,
    17. Tephly TR,
    18. Tipton KF,
    19. Nebert DW
    (1997) The UDP glycosyltransferase gene superfamily: Recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 7:255–269.
    OpenUrlCrossRefPubMed
  35. ↵
    1. Maltepe E,
    2. Schmidt JV,
    3. Baunoch D,
    4. Bradfield CA,
    5. Simon MC
    (1997) Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT. Nature 386:403–407.
    OpenUrlCrossRefPubMed
  36. ↵
    1. McManus ME,
    2. Burgess WM,
    3. Veronese ME,
    4. Huggett A,
    5. Quattrochi LC,
    6. Tukey RH
    (1990) Metabolism of 2-acetylaminofluorene, benzo[a]pyrene and the activation of food derived heterocyclic amine mutagens by human cytochromes P450. Cancer Res 50:3367–3376.
    OpenUrlAbstract/FREE Full Text
  37. ↵
    1. Merrill AH, Jr,
    2. Wang E,
    3. LaRocque R,
    4. Mullins RE,
    5. Morgan ET,
    6. Hargrove JL,
    7. Bonkovsky HL,
    8. Popova IA
    (1992) Differences in glycogen, lipids, and enzymes in livers of rats flown on COSMOS 2044. J Appl Physiol 73:142S–147S.
  38. ↵
    1. Morgan ET
    (1997) Regulation of cytochromes P450 during inflammation and infection. Drug Metab Rev 29:1129–1188.
    OpenUrlPubMed
  39. ↵
    1. Morgan ET,
    2. MacGeoch C,
    3. Gustafsson J-Å
    (1985) Hormonal and developmental regulation of expression of the hepatic microsomal steroid 16α-hydroxylase cytochrome P-450 apoprotein in the rat. J Biol Chem. 260:11895–11898.
    OpenUrlAbstract/FREE Full Text
  40. ↵
    1. Nikolova-Karakashian M,
    2. Morgan ET,
    3. Alexander C,
    4. Liotta DC,
    5. Merrill AH, Jr
    (1997) Bimodal regulation of ceramidase by interleukin-1β: Implications for the regulation of cytochrome P450 2C11 (CYP2C11). J Biol Chem 272:18718–18724.
    OpenUrlAbstract/FREE Full Text
  41. ↵
    1. Okino ST,
    2. Pendurthi UR,
    3. Tukey RH
    (1992) Phorbol esters inhibit the dioxin receptor mediated transcriptional activation of the mouse Cyp1A1 and Cyp1A2 genes by 2,3,7,8-tetrachlorodibenzo-p-dioxin. J Biol Chem 267:6991–6998.
    OpenUrlAbstract/FREE Full Text
  42. ↵
    1. Okino ST,
    2. Whitlock JP, Jr
    (1995) Dioxin induces localized, graded changes in chromatin structure: Implications for Cyp1A1 gene transcription. Mol Cell Biol 15:3714–3721.
    OpenUrlAbstract/FREE Full Text
  43. ↵
    1. Omiecinski CJ
    (1986) Tissue-specific expression of rat mRNAs homologous to cytochromes P-450b and P-450e. Nucleic Acids Res 14:1525–1539.
    OpenUrlAbstract/FREE Full Text
  44. ↵
    1. Owens IS,
    2. Ritter JK
    (1995) Gene structure at the human UGT1 locus creates diversity in isozyme structure, substrate specificity, and regulation. Prog Nucleic Acid Res Mol Biol 51:305–338.
    OpenUrlPubMed
  45. ↵
    1. Park Y,
    2. Li H,
    3. Kemper B
    (1996) Phenobarbital induction mediated by a distal CYP2B2 sequence in rat liver transiently transfected in situ. J Biol Chem 271:23725–23728.
    OpenUrlAbstract/FREE Full Text
  46. ↵
    1. Pendurthi UR,
    2. Okino ST,
    3. Tukey RH
    (1993) Accumulation of the nuclear dioxin (Ah)-receptor and transcriptional activation of the mouse Cyp1a-1 and Cyp1a-2 genes. Arch Biochem Biophys 306:65–69.
    OpenUrlCrossRefPubMed
  47. ↵
    1. Pimental RA,
    2. Liang B,
    3. Yee GK,
    4. Wilhelmsson A,
    5. Poellinger L,
    6. Paulson KE
    (1993) Dioxin receptor and C/EBP regulate the function of the glutathione S-transferase Ya gene xenobiotic response element. Mol Cell Biol 13:4365–4373.
    OpenUrlAbstract/FREE Full Text
  48. ↵
    1. Pollenz RS,
    2. Sattler CA,
    3. Poland A
    (1994) The aryl hydrocarbon receptor and aryl hydrocarbon receptor nuclear translocator protein show distinct subcellular localizations in hepa 1c1c7 cells by immunofluorescence microscopy. Mol Pharmacol 45:428–438.
    OpenUrlAbstract
  49. ↵
    1. Pontoglio M,
    2. Barra J,
    3. Hadchouel M,
    4. Doyen A,
    5. Kress C,
    6. Bach JP,
    7. Babinet C,
    8. Yaniv M
    (1996) Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome. Cell 84:575–585.
    OpenUrlCrossRefPubMed
  50. ↵
    1. Postlind H,
    2. Vu TP,
    3. Tukey RH,
    4. Quattrochi LC
    (1992) Response of human CYP-Luciferase plasmids to 2,3,7,8-tetrachlorodibenzo-p-dioxin and polycyclic aromatic hydrocarbons. Toxicol Appl Pharmacol 118:265–262.
    OpenUrl
  51. ↵
    1. Quattrochi LC,
    2. Tukey RH
    (1993) Nuclear uptake of the Ah (dioxin) receptor in response to omeprazole: Transcriptional activation of the human CYP1A1 gene. Mol Pharmacol 43:504–508.
    OpenUrlAbstract
  52. ↵
    1. Ramsden R,
    2. Sommer KM,
    3. Omiecinski CJ
    (1993) Phenobarbital induction and tissue-specific expression of the rat CYP2B2 gene in transgenic mice. J Biol Chem 268:21722–21726.
    OpenUrlAbstract/FREE Full Text
  53. ↵
    1. Reyes H,
    2. Reisz-Porszasz S,
    3. Hankinson O
    (1992) Identification of the Ah receptor nuclear translocator protein (Arnt) as a component of the DNA binding form of the Ah receptor. Science 256:1193–1195.
    OpenUrlAbstract/FREE Full Text
  54. ↵
    1. Rowlands JC,
    2. Gustafsson JA
    (1997) Aryl hydrocarbon receptor-mediated signal transduction. Crit Rev Toxicol 27:109–134.
    OpenUrlCrossRefPubMed
  55. ↵
    1. Schwenk F,
    2. Kuhn R,
    3. Angrand PO,
    4. Rajewsky K,
    5. Stewart AF
    (1998) Temporally and spatially regulated somatic mutagenesis in mice. Nucleic Acids Res 26:1427–1432.
    OpenUrlAbstract/FREE Full Text
  56. ↵
    1. Sewer MB,
    2. Barclay TB,
    3. Morgan ET
    (1998) Down-regulation of cytochrome P450 mRNAs and proteins in mice lacking a functional NOS2 gene. Mol Pharmacol 54:273–279.
    OpenUrlAbstract/FREE Full Text
  57. ↵
    1. Sewer MB,
    2. Koop DR,
    3. Morgan ET
    (1997) Differential inductive and suppressive effects of endotoxin and particulate irritants on hepatic and renal cytochrome P-450 expression. J Pharmacol Exp Ther 280:1445–1454.
    OpenUrlAbstract/FREE Full Text
  58. ↵
    1. Sewer MB,
    2. Morgan ET
    (1997) Nitric oxide independent suppression of P-450 2C11 expression by interleukin-1β and endotoxin in primary rat hepatocytes. Biochem Pharmacol 54:729–737.
    OpenUrlCrossRefPubMed
  59. ↵
    1. Sewer MB,
    2. Morgan ET
    (1998) Down-regulation of the expression of three major rat liver cytochrome P450s by endotoxin in vivo occurs independently of NO production. J Pharmacol Exp Ther 287:352–358.
    OpenUrlAbstract/FREE Full Text
  60. ↵
    1. Shaw GC,
    2. Fulco AJ
    (1993) Inhibition by barbiturates of the binding of Bm3R1 repressor to its operator site on the barbiturate-inducible cytochrome P450BM-3 gene of Bacillus megaterium. J Biol Chem 268:2997–3004.
    OpenUrlAbstract/FREE Full Text
  61. ↵
    1. Shaw GC,
    2. Sung CC,
    3. Liu CH,
    4. Lin CH
    (1998) Evidence against the Bm1P1 protein as a positive transcription factor for barbiturate-mediated induction of cytochrome P450BM1 in Bacillus megaterium. J Biol Chem 273:7996–8002.
    OpenUrlAbstract/FREE Full Text
  62. ↵
    1. Sidhu JS,
    2. Omiecinski CJ
    (1995) cAMP-associated inhibition of phenobarbital-inducible cytochrome P450 gene expression in primary rat hepatocyte cultures. J Biol Chem 270:12762–12773.
    OpenUrlAbstract/FREE Full Text
  63. ↵
    1. Sidhu JS,
    2. Omiecinski CJ
    (1997) An okadaic acid-sensitive pathway involved in the phenobarbital-mediated induction of CYP2B gene expression in primary rat hepatocyte cultures. J Pharmacol Exp Ther 282:1122–1129.
    OpenUrlAbstract/FREE Full Text
  64. ↵
    1. Sidhu JS,
    2. Omiecinski CJ
    (1998) Protein synthesis inhibitors exhibit a nonspecific effect on phenobarbital-inducible cytochrome P450 gene expression in primary rat hepatocytes. J Biol Chem 273:4769–4775.
    OpenUrlAbstract/FREE Full Text
  65. ↵
    1. Sommer KM,
    2. Ramsden R,
    3. Sidhu J,
    4. Costa P,
    5. Omiecinski CJ
    (1996) Promoter region analysis of the rat CYP2B1 and CYP2B2 genes. Pharmacogenetics 6:369–374.
    OpenUrlCrossRefPubMed
  66. ↵
    1. Stoltz C,
    2. Vachon M,
    3. Trottier E,
    4. Dubois S,
    5. Paquet Y,
    6. Anderson A
    (1998) The CYP2B2 phenobarbital response unit contains an accessory factor element and a putative glucocorticoid response element essential for conferring maximal phenobarbital responsiveness. J Biol Chem 273:8528–8536.
    OpenUrlAbstract/FREE Full Text
  67. ↵
    1. Telakowski-Hopkins CA,
    2. King RG,
    3. Pickett CB
    (1988) Glutathione S-transferase Ya subunit gene: Identification of regulatory elements required for basal level and inducible expression. Proc Natl Acad Sci USA 85:1000–1004.
    OpenUrlAbstract/FREE Full Text
  68. ↵
    1. Torres RM,
    2. Kuhn R
    (1997) Laboratory Protocols for Conditional Gene Targeting. (Oxford University Press, New York).
  69. ↵
    1. Tronche F,
    2. Rollier A,
    3. Herbomel P,
    4. Bach I,
    5. Cereghini S,
    6. Weiss M,
    7. Yaniv M
    (1990) Anatomy of the rat albumin promoter. Mol Biol Med 7:173–185.
    OpenUrlPubMed
  70. ↵
    1. Trottier E,
    2. Belzil A,
    3. Stoltz C,
    4. Anderson A
    (1995) Localization of a phenobarbital-responsive element (PBRE) in the 5′-flanking region of the rat CYP2B2 gene. Gene 158:263–268.
    OpenUrlCrossRefPubMed
  71. ↵
    1. Tukey RH,
    2. Hannah RR,
    3. Negishi M,
    4. Nebert DW,
    5. Eisen HJ
    (1982) The Ah locus: Correlation of intranuclear appearance of inducer-receptor complex with induction of cytochrome P1-450 mRNA. Cell 31:275–284.
    OpenUrlCrossRefPubMed
  72. ↵
    1. Tukey RH,
    2. Nebert DW,
    3. Negishi M
    (1981) Structural gene product of the Ah complex: Evidence for transcriptional control of cytochrome P1-450 induction by use of a cloned DNA sequence. J Biol Chem 256:6969–6974.
    OpenUrlFREE Full Text
  73. ↵
    1. Wang ND,
    2. Finegold MJ,
    3. Bradley A,
    4. Ou CN,
    5. Abdelsayed SV,
    6. Wilde MD,
    7. Taylor LR,
    8. Wilson DR,
    9. Darlington GJ
    (1995) Impaired energy homeostasis in C/EBP alpha knockout mice. Science 269:1108–1112.
    OpenUrlAbstract/FREE Full Text
  74. ↵
    1. Waxman DJ,
    2. Azaroff L
    (1992) Phenobarbital induction of cytochrome P-450 gene expression. Biochem J 281:577–592.
  75. ↵
    1. Weber TJ,
    2. Ou X,
    3. Merchant M,
    4. Wang X,
    5. Safe SH,
    6. Ramos KS
    (1994) Biphasic modulation of protein kinase C (PKC) activity by polychlorinated dibenzo-p-dioxins (PCDDs) in serum-deprived rat aortic smooth muscle cells. J Biochem Toxicol 9:113–120.
    OpenUrlCrossRefPubMed
  76. ↵
    1. Whitelaw M,
    2. Pongratz I,
    3. Wilhelmsson A,
    4. Gustafsson J-Å,
    5. Poellinger L
    (1993) Ligand-dependent recruitment of the Arnt coregulator determines DNA recognition by the dioxin receptor. Mol Cell Biol 13:2504–2514.
    OpenUrlAbstract/FREE Full Text
  77. ↵
    1. Wink DA,
    2. Osawa Y,
    3. Darbyshire JF,
    4. Jones CR,
    5. Eshenaur SC,
    6. Nims RW
    (1993) Inhibition of cytochromes P450 by nitric oxide and a nitric oxide-releasing agent. Arch Biochem Biophys 300:115–123.
    OpenUrlCrossRefPubMed
  78. ↵
    1. Wojcik E,
    2. Dvorak C,
    3. Chianale J,
    4. Traber PG,
    5. Keren D,
    6. Gumucio JJ
    (1988) Demonstration by in situ hybridization of the zonal modulation of rat liver cytochrome P-450b and P-450e gene expression after phenobarbital. J Clin Invest 82:658–666.
View Abstract
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleArticle

Physiological and Pathophysiological Regulation of Cytochrome P450

Edward T. Morgan, Marion B. Sewer, Heinrich Iber, Frank J. Gonzalez, Ying-Hue Lee, Robert H. Tukey, Steve Okino, Tien Vu, Yue-Hwa Chen, Jaspreet S. Sidhu and Curtis J. Omiecinski
Drug Metabolism and Disposition December 1, 1998, 26 (12) 1232-1240;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section